La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Voyager Therapeutics Résultats passés
Passé contrôle des critères 1/6
Informations clés
36.2%
Taux de croissance des bénéfices
35.9%
Taux de croissance du BPA
Biotechs Croissance de l'industrie | 17.0% |
Taux de croissance des recettes | 10.5% |
Rendement des fonds propres | 2.7% |
Marge nette | 6.3% |
Dernière mise à jour des bénéfices | 30 Jun 2024 |
Mises à jour récentes des performances passées
Recent updates
Earnings Beat: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Aug 09Lacklustre Performance Is Driving Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Low P/S
Aug 08Voyager: Alzheimer's Clinical Trial Start (VY-TAU01) Strengthens Investment Thesis
Jun 05There's No Escaping Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Muted Revenues Despite A 28% Share Price Rise
Mar 15Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier
Mar 08What Does The Future Hold For Voyager Therapeutics, Inc. (NASDAQ:VYGR)? These Analysts Have Been Cutting Their Estimates
Mar 04Voyager Therapeutics, Inc. (NASDAQ:VYGR) Surges 45% Yet Its Low P/S Is No Reason For Excitement
Jan 04Voyager stock rises as Pfizer opts to use AAV capsid for neurologic disease target
Oct 04Voyager Therapeutics hires new finance chief
Sep 07Voyager Therapeutics GAAP EPS of -$0.50 misses by $0.02
Aug 04Looking Back In On Voyager Therapeutics
Jun 08Need To Know: Analysts Just Made A Substantial Cut To Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Estimates
May 12Voyager Does A Reboot After First Generation Failures
Mar 25Companies Like Voyager Therapeutics (NASDAQ:VYGR) Could Be Quite Risky
Feb 07Voyager Therapeutics: Another Year, Another Deal
Nov 21Ventilation des recettes et des dépenses
Ventilation des recettes et des dépenses
Comment Voyager Therapeutics gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
---|---|---|---|---|
30 Jun 24 | 144 | 9 | 37 | 0 |
31 Mar 24 | 119 | -3 | 35 | 0 |
31 Dec 23 | 250 | 132 | 36 | 0 |
30 Sep 23 | 158 | 52 | 34 | 0 |
30 Jun 23 | 195 | 96 | 33 | 0 |
31 Mar 23 | 191 | 99 | 32 | 0 |
31 Dec 22 | 41 | -46 | 31 | 0 |
30 Sep 22 | 71 | -17 | 31 | 0 |
30 Jun 22 | 31 | -60 | 32 | 0 |
31 Mar 22 | 32 | -71 | 35 | 0 |
31 Dec 21 | 37 | -71 | 37 | 0 |
30 Sep 21 | 16 | -93 | 37 | 0 |
30 Jun 21 | 132 | 18 | 37 | 0 |
31 Mar 21 | 160 | 39 | 35 | 0 |
31 Dec 20 | 171 | 37 | 35 | 0 |
30 Sep 20 | 197 | 40 | 37 | 0 |
30 Jun 20 | 100 | -61 | 37 | 0 |
31 Mar 20 | 117 | -41 | 37 | 0 |
31 Dec 19 | 104 | -44 | 36 | 0 |
30 Sep 19 | 74 | -54 | 40 | 0 |
30 Jun 19 | 55 | -59 | 38 | 0 |
31 Mar 19 | 12 | -96 | 36 | 0 |
31 Dec 18 | 8 | -88 | 34 | 0 |
30 Sep 18 | 12 | -78 | 26 | 0 |
30 Jun 18 | 11 | -81 | 24 | 0 |
31 Mar 18 | 10 | -74 | 22 | 0 |
31 Dec 17 | 10 | -71 | 20 | 0 |
30 Sep 17 | 6 | -74 | 18 | 0 |
30 Jun 17 | 8 | -59 | 16 | 0 |
31 Mar 17 | 11 | -50 | 15 | 0 |
31 Dec 16 | 14 | -40 | 13 | 0 |
30 Sep 16 | 17 | -34 | 13 | 0 |
30 Jun 16 | 18 | -32 | 12 | 0 |
31 Mar 16 | 20 | -30 | 12 | 0 |
31 Dec 15 | 17 | -38 | 10 | 0 |
30 Sep 15 | 12 | -35 | 8 | 0 |
30 Jun 15 | 7 | -32 | 7 | 0 |
31 Mar 15 | 3 | -30 | 6 | 0 |
31 Dec 14 | 0 | -18 | 5 | 0 |
Augmentation de la marge bénéficiaire: VYGR's current net profit margins (6.3%) are lower than last year (49.2%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: VYGR has become profitable over the past 5 years, growing earnings by 36.2% per year.